Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Undiagnosed peripheral artery disease common among high-risk patients

19 May 2019

Undiagnosed peripheral arterial disease (PAD) is common among high-risk patients, reports a new Australia study.

Drawing from the Australian Reduction of Atherothrombosis for Continued Health Registry, researchers identified 2,489 patients (mean age, 72.8±8.8 years; 65.3 percent male) who were at high risk of atherothrombosis. Only those without prior PAD diagnoses and had an ankle-brachial index (ABI) <1.4 at recruitment were eligible.

Of the participants, 34 percent were positive for PAD, with around 28 percent having low ABI (ABI+’; ABI<0.9) and 11 percent having intermittent claudication (IC). Overall, the rates of all-cause mortality and PAD events in the overall cohort were low, at 2 percent and 1.2 percent, respectively.

Disaggregation showed that all-cause mortality (2.9 percent vs 1.6 percent) and PAD events (2.1 percent vs 0.9 percent) occurred more commonly in ABI+ patients. IC patients, on the other hand, were more likely to experience nonfatal events (11.8 percent vs 8.3 percent) and PAD events (4.8 percent vs 0.8 percent). Moreover, Cox regression analysis found that PAD events were more likely to occur in patients who were positive for IC, regardless of whether IC was normal or low.

One-year follow-up data was available for 2,013 patients, of whom 123 (6 percent) developed IC. In this group, the risk of IC was 1.6-times higher in participants with low ABI as compared with those who had normal ABI values.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.